Skip to main content

Month: January 2024

Stryker to announce financial results for its fourth quarter and full year 2023

Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter and full year 2023 on Tuesday, January 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker – Press Releases that day. The press release will include summary financial information for the company’s fourth quarter and full year 2023, that ended December 31, 2023. Stryker will host a webcast at 4:30pm ET on Tuesday, January 30, 2024, to discuss results for its fourth quarter and full year 2023.  The webcast can be accessed at Stryker – Events & Presentations.  An archive of the webcast will also be available on the company’s website two hours after the live call ends. About Stryker Stryker is one of the world’s leading medical technology...

Continue reading

First ReWalk Personal Exoskeleton Claim Paid by Medicare

ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injury MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced that it has received payment from Noridian Healthcare Solutions (“Noridian”), a Medicare Administrative Contractor (“MAC”), for its first claim for the ReWalk Personal Exoskeleton. This marks coverage and payment by Medicare fee-for-service for the first-ever claim submitted for a ReWalk Personal Exoskeleton device. This milestone reflects an acknowledgement by Medicare that the ReWalk Personal...

Continue reading

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness, and serious disease, advises that it has received formal notice from the Nasdaq Stock Market, LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on July 17, 2023, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. To regain compliance with the Listing Rule, the Company’s American Depositary Shares (ADS) were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive...

Continue reading

Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements

Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has finalized a series of updated commercial arrangements with its long-term commercial Hyaluronic Acid and CDMO customer, Alcon (SIX/NYSE: ALC) (Alcon) to extend and expand the existing CDMO relationship. Additionally, the Company also entered into a limited waiver and amendment to its credit agreements with Alcon and with BMO to, among other things, waive certain financial reporting delivery requirements....

Continue reading

Global Fitness App Market to Reach Value of USD 4700 million by 2030 | Skyquest Technology

Global fitness app market is segmented by type, and application. Based on type, the market can be segmented into workout and exercise apps, and diet and nutrition apps. Based on application, the market is segmented into smartphones and tablets- Industry forecast 2023-2030 Westford,USA, Jan. 05, 2024 (GLOBE NEWSWIRE) — According to SkyQuest report, the fitness app market has witnessed a profound transformation to the rapid advancements in technology, which have sparked intense competition between traditional brick-and-mortar gyms and digital, in-app fitness solutions. Browse in-depth TOC on the “Fitness App Market”       Pages – 157 Tables –  60 Figures – 75The burgeoning working population has created a fast-paced and demanding lifestyle, leaving limited time for dedicated fitness routines. This shifting...

Continue reading

RCLCO Ranks Summerlin® and Bridgeland® Among Nation’s Top Five Best-Selling Master Planned Communities of 2023

Howard Hughes Communities Distinguished by Strong New Home SalesSummerlin®, a Howard Hughes Community in Las Vegas, NevadaSummerlin® ranks #4 on RCLCO’s national list of top-selling master planned communities for 2023Bridgeland®, a Howard Hughes Community in the Greater Houston, Texas areaBridgeland® ranks #5 on RCLCO’s national list of top-selling master planned communities for 2023THE WOODLANDS, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) — Summerlin® and Bridgeland®, two of the award-winning communities in the Howard Hughes Holdings Inc. (NYSE: HHH) portfolio, have been ranked among the nation’s top five best-selling master planned communities (MPCs) for 2023, according to the year-end report released by national real estate consultant RCLCO. Summerlin, in Las Vegas, Nevada, ranked #4 on the RCLCO list with a 39%...

Continue reading

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity – Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity. Effectiveness of GLP-1ra non T2D obesity was recently shown in the >17,600 patient SELECT trial by Novo Nordisk (N Engl J Med 2023; 389:2221-2232(NCT03574597). SELECT showed a 20% reduction of major adverse cardiovascular events (MACE) such as heart attack, stroke, and peripheral vascular disease, with semaglutide....

Continue reading

Clean Earth Names New Chief Commercial Officer

KING OF PRUSSIA, Pa., Jan. 05, 2024 (GLOBE NEWSWIRE) — Clean Earth, a division of Enviri Corporation (NYSE: NVRI) and a leading provider of environmental and regulated waste management services, today announced that Liz Peterson will be appointed Chief Commercial Officer effective January 8, 2024. In this newly created role, Peterson will be responsible for all commercial strategy, customer experience, sales initiatives, and sales operations. All commercial teams and activities under Clean Earth’s Hazardous Waste and Soil and Dredge Material lines of business will work under Peterson’s leadership. With more than 30 years of diversified environmental services experience, Peterson served as Senior Vice President at Badger Infrastructure Solutions, a leading hydro-excavation provider in North America. Her comprehensive responsibilities...

Continue reading

Pan American Energy Corp Announces Filing of Inaugural NI 43-101 Technical Report For The Horizon Lithium Project

The maiden Mineral Resource Estimate included in the Technical Report Is One of The Largest Identified Lithium Deposits in the United States, Totaling Over 1.3 million tonnes of Indicated and 8.8 million tonnes of Inferred Lithium Carbonate Equivalent ResourcesFigure 1The Project boundary, 20 exploratory drillholes used in the MRE, and the Mineral resource body showing unexplored areas to the west, northwest, east and south.CALGARY, Alberta, Jan. 05, 2024 (GLOBE NEWSWIRE) — Pan American Energy Corp. (CSE:PNRG) (OTCQB: PAANF) (FRA: SS60) (“Pan American” or the “Company”) is pleased to announce that, further to its news release dated November 20, 2023 announcing the maiden mineral resource estimate (the “MRE”) for the Horizon Lithium Project (the “Project”), it has filed a technical report pursuant to National Instrument...

Continue reading

Wabash Schedules Fourth Quarter 2023 Earnings Conference Call

LAFAYETTE, Ind., Jan. 05, 2024 (GLOBE NEWSWIRE) — Wabash (NYSE: WNC) today announced that it will webcast its quarterly earnings conference call to review and discuss its financial results for the fourth quarter 2023 on Thursday, February 1, 2024 beginning at 11:00 a.m. ET. The call and an accompanying slide presentation will be accessible on the “Investors” section of Wabash’s website, www.onewabash.com, under “Events & Presentations.” The conference call will be accessible by dialing (888) 440-6928, conference ID 6579482. A replay of the call will be available shortly after the conclusion of the presentation and will remain available for one year following the date of the call. Access to the replay will be available on the “Investors” section of Wabash’s website under “Events &...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.